Table 2: Metabolic and hemodynamic responses at rest, during and after exercise in T2D patients and control subjects during placebo and CoQ10 conditions.
Group |
T2D (n = 7) |
Control (n = 7) |
P |
P |
P |
||
Trial |
Placebo |
CoQ10 |
Placebo |
CoQ10 |
Group |
Tx |
Inter |
Resting |
|
|
|
|
|
|
|
PCr (mM) |
39.12 ± 1.98 |
38.93 ± 3.66 |
41.09 ± 2.13 |
39.82 ± 1.76 |
0.459 |
0.637 |
0.358 |
Pi (mM) |
5.84 ± 1.07 |
4.99 ± 1.75 |
4.78 ± 1.06 |
4.61 ± 0.95 |
0.237 |
0.518 |
0.695 |
ipH |
7.02 ± 0.02 |
7.00 ± 0.02 |
7.01 ± 0.04 |
7.02 ± 0.01 |
0.329 |
0.319 |
0.218 |
Exercise |
|
|
|
|
|
|
|
SSI Ex. Duration (s) |
312.8 ± 117.6 |
321.7 ± 135.5 |
408.9 ± 103.5 |
424.6 ± 88.3 |
0.030 |
0.720 |
1.00 |
NIRS |
|
|
|
|
|
|
|
T50 |
70.93 ± 52.13 |
69.10 ± 33.72 |
31.83 ± 8.36 |
32.43 ± 10.02 |
0.004 |
0.960 |
0.920 |
BFindex (%/s) |
5.33 ± 2.88 |
3.99 ± 2.23 |
9.74 ± 2.92 |
9.22 ± 2.42 |
0.010 |
0.469 |
0.736 |
MRS |
|
|
|
|
|
|
|
End PCr (mM) |
45.58 ± 17.24 |
42.13 ± 4.68 |
49.4 ± 17.60 |
51.76 ± 14.57 |
0.562 |
0.632 |
0.980 |
PCrre (mM·kg·min-1) |
22.31 ± 13.35 |
23.20 ± 11.39 |
49.37 ± 36.61 |
43.74 ± 33.28 |
0.034 |
0.905 |
0.960 |
Tc (s) |
67.21 ± 69.51 |
53.61 ± 22.55 |
35.59 ± 23.65 |
32.54 ± 15.18 |
0.014 |
0.802 |
0.770 |
pH End ex. (12-s) |
6.979 ± 0.074 |
6.96 ± 0.036 |
7.002 ± 0.036 |
7.004 ±0.049 |
0.094 |
0.663 |
0.586 |
pH 1 min post ex. (12-s) |
6.886 ± 0.064 |
6.915 ± 0.063 |
6.972 ± 0.038 |
6.988 ± 0.059 |
0.001 |
0.311 |
0.793 |
Note: PCr: Phosphocreatine; Pi: Inorganic phosphate; ipH: intracellular pH; T50NIR: Time to 50% of Hemoglobin/Myoglobin-reoxygenation from cessation of exercise; BFindex: Blood flow index; End PCr: End exercise PCr; PCrre: Phosphocreatine resynthesis rate; Tc: Time constant; 12-s: 12-s all out exercise; SSI: steady state incremental exercise. Data are expressed in mean ± SD.